Chris Lau

Chris Lau

InvestorPlace Contributor

Expertise: Technology, Biotech

Expertise:

Technology
Biotech

Education:

Bachelor of Science
Project Management Professional

Awards and Accomplishments:

Top 100 Tipranks 2015-2021

About Chris:

Chris has over two decades of investing experience. He is an Honors B.Sc graduate (with distinction) in Science and Economics. He holds a Project Management Professional designation

Chris focuses on the technology, cyclical, and healthcare sector. He runs a newsletter with speculative Triple-baggers.

His investment strategy is based on finding undervalued stocks trading at a steep discount to their intrinsic value.

Follow Chris on DIY Value Investing.

Recent Articles

CRISPR Therapeutics Rallies as Gene Stocks Get Hot Again

By Chris Lau, InvestorPlace Contributor

CRSP is testing its gene editing therapies in sicke cell disease and cancer. These therapies could eventually boost CRSP stock.

Expect More Upside From Etsy Stock, Regardless of Earnings

By Chris Lau, InvestorPlace Contributor

Etsy (NASDAQ:ETSY) is scheduled to report fourth-quarter earnings results after the market close Monday. After trading at yearly highs intraday, ahead of results, markets clearly…

Facebook Stock Is Still Poised for a Strong Comeback

By Chris Lau, InvestorPlace Contributor

Facebook faces higher costs and slowing revenue for 2019. This might scare off short-term FB stock speculators, while patient investors need not worry.

Is Stamps.com Stock a Hopeless Investment After Disappointing Guidance?

By Chris Lau, InvestorPlace Contributor

STMP stock could be at the start of a long bearish phase, as markets adjust to the lack of revenue growth from Stamps.com for years to come.

Why Activision Stock May Rally in 2020

By Chris Lau, InvestorPlace Contributor

Activision's emphasis on digital games and its deal in China could boost the 2020 results of ATVI/ As a result, Activision stock could rise.

Load More